Cargando…

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy

CD47 and its receptor signal regulatory protein α (SIRPα) act as a dominant antiphagocytic, “don’t eat me” signal. Recent studies reveal CD24 as a novel target for cancer immunotherapy by macrophages in ovarian cancer and breast cancer. However, whether simultaneous blockade of CD47 and CD24 by a bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yun, Wu, He, Yang, Yan, Kang, Yan, He, Runjia, Zhou, Bei, Guo, Huaizu, Zhang, Jing, Li, Jianqin, Ge, Chunpo, Wang, Tianyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689933/ https://www.ncbi.nlm.nih.gov/pubmed/38046893 http://dx.doi.org/10.1016/j.omto.2023.100747

Ejemplares similares

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
por: Dheilly, Elie, et al.
Publicado: (2017)

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
por: Dheilly, Elie, et al.
Publicado: (2018)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
por: Wang, Rongjuan, et al.
Publicado: (2023)

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
por: Candas-Green, Demet, et al.
Publicado: (2020)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
por: Vitale, Laura A., et al.
Publicado: (2020)

CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors
por: Liu, Xiaojuan, et al.
Publicado: (2015)

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
por: Lin, Fangzhen, et al.
Publicado: (2021)

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
por: Zeller, Tobias, et al.
Publicado: (2022)

Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma
por: Wu, Hao, et al.
Publicado: (2021)

TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma
por: Peng, Yue, et al.
Publicado: (2022)

The landscape overview of CD47-based immunotherapy for hematological malignancies
por: Yang, Hua, et al.
Publicado: (2023)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
por: Chang, Rui, et al.
Publicado: (2023)

Targeting CD24 as a novel immunotherapy for solid cancers
por: Yang, Yan, et al.
Publicado: (2023)

The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination
por: Shi, Rui, et al.
Publicado: (2020)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

CD47 blockade enhances phagocytosis of cardiac cell debris by neutrophils
por: Haj-Yehia, Elias, et al.
Publicado: (2023)

Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy
por: Xie, Zhongjian, et al.
Publicado: (2020)

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
por: Yu, Jifeng, et al.
Publicado: (2022)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
por: Chen, Can, et al.
Publicado: (2022)

PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
por: Yang, Zhenlin, et al.
Publicado: (2021)

CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models
por: Xu, Ji-Feng, et al.
Publicado: (2015)

Synergistic effect of CD47 blockade in combination with cordycepin treatment against cancer
por: Feng, Chen, et al.
Publicado: (2023)

Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation
por: Hatterer, Eric, et al.
Publicado: (2019)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
por: Tian, Ziyin, et al.
Publicado: (2022)

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
por: Lian, Shu, et al.
Publicado: (2019)

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41
por: Yan, Hongxia, et al.
Publicado: (2022)

P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
por: Grandclement, C., et al.
Publicado: (2022)

Blockade of CD47 increases survival of mice exposed to lethal total body irradiation
por: Soto-Pantoja, David R., et al.
Publicado: (2013)

CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes
por: Kosaka, Akemi, et al.
Publicado: (2021)

Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect
por: Nishiga, Yoko, et al.
Publicado: (2022)

CD47 blockade ameliorates autoimmune vasculitis via efferocytosis of neutrophil extracellular traps
por: Shiratori-Aso, Satoka, et al.
Publicado: (2023)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8viiei9cgbla5tpmb3bn9j2mop